Alnylam Submits IND Application for ALN-RSV01
News Nov 02, 2005
Alnylam Pharmaceuticals, Inc. has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a human clinical trial of ALN-RSV01, its proprietary RNAi therapeutic for the treatment of patients with respiratory syncytial virus (RSV) infection.
Following clearance of the IND by the FDA, Alnylam plans to initiate a Phase I safety study in healthy adult volunteers, representing the first program the company will have advanced to human clinical trials. Alnylam is also preparing to initiate a Phase I trial in Europe.
"Submission of our IND for ALN-RSV01 is a major milestone towards Alnylam's goal of developing and commercializing RNAi therapeutics to treat important diseases with significant unmet medical need. Pending IND clearance, we expect to initiate human clinical studies by year-end," said John Maraganore, Ph.D., President and Chief Executive Officer of Alnylam.
"ALN-RSV01, our first Direct RNAi program to enter the clinical phase, represents a novel approach for the treatment of RSV. This program is a clear example of the potential for RNAi therapeutics both to target previously 'non-druggable' targets and to treat major infectious diseases."
ALN-RSV01 is believed to be the most advanced RNAi therapeutic for the treatment of infectious diseases caused by a virus. It is also the only RNAi therapeutic known to be in development for the treatment of RSV infection, a major cause of respiratory illness in young children, the elderly and in immune-deficient patient populations.
"Effective antiviral drugs to treat RSV infection, particularly in pediatric populations, are greatly needed as RSV infection is the leading cause of infant hospitalizations in the United States," said John P. DeVincenzo, M.D., Associate Professor of Pediatrics at the University of Tennessee Health Science Center.
"Based on the encouraging pre-clinical data for ALN-RSV01, and a novel mechanism of action demonstrating impressive antiviral target specificity, I'm excited about the potential of advancing this promising new therapy into clinical trials."
ALN-RSV01 selectively and potently silences the RSV nucleocapsid 'N' gene. This gene is among the most highly conserved genes in the virus and is essential for RSV replication. Data presented to date show both in vitro and in vivo efficacy of ALN-RSV01 in pre-clinical animal studies.
Intranasally delivered ALN-RSV01 specifically inhibits RSV replication in animals and is active in the prevention and treatment of RSV infection. Additionally, Alnylam scientists have reported completion of GLP toxicology studies for ALN-RSV01 without any significant toxicities being observed.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.